Luc Mouthon

Q: What Schools Are Affiliated With Luc Mouthon

Luc Mouthon is affiliated with the following schools: Université Paris Cité, ETH Zurich, Stanford University, Paris Diderot University

Luc Mouthon's AcademicInfluence.com Rankings

Luc Mouthon

Computer Science

#4895

World Rank

#5167

Historical Rank

Data Science

#71

World Rank

#73

Historical Rank

Computational Linguistics

#564

World Rank

#574

Historical Rank

Machine Learning

#1106

World Rank

#1124

Historical Rank

computer-science Degrees

Luc Mouthon

Mathematics

#5869

World Rank

#8221

Historical Rank

Measure Theory

#991

World Rank

#1285

Historical Rank

mathematics Degrees

Download Badge

Computer Science
Mathematics

Luc Mouthon's Degrees

PhD Computer Science Université Paris Cité
Masters Computer Science Université Paris Cité
Bachelors Mathematics Université Paris Cité

Similar Degrees You Can Earn

Why Is Luc Mouthon Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Luc Mouthon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients (2020) (1962)
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. (2014) (801)
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. (2005) (738)
The Five-Factor Score Revisited: Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort (2011) (679)
Inflammation, growth factors, and pulmonary vascular remodeling. (2009) (663)
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. (2013) (622)
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. (2008) (582)
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 (2020) (537)
Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. (2010) (431)
Antineutrophil Cytoplasmic Antibodies and the ChurgStrauss Syndrome (2005) (375)
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data (2020) (367)
Self-reactive antibodies (natural autoantibodies) in healthy individuals. (1998) (343)
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. (2015) (339)
Common Variable Immunodeficiency Patient Classification Based on Impaired B Cell Memory Differentiation Correlates with Clinical Aspects (2003) (329)
Mapping and predicting mortality from systemic sclerosis (2017) (328)
Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. (2005) (319)
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. (2003) (311)
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. (2008) (292)
Vasculitides associated with malignancies: analysis of sixty patients. (2007) (275)
Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action (2007) (257)
Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. (2007) (243)
Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients (2020) (241)
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. (2008) (228)
Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. (2003) (225)
Deaths Occurring During the First Year After Treatment Onset for Polyarteritis Nodosa, Microscopic Polyangiitis, and Churg-Strauss Syndrome: A Retrospective Analysis of Causes and Factors Predictive of Mortality Based on 595 Patients (2005) (222)
Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. (2011) (220)
Pathogenesis of hemophagocytic syndrome (HPS). (2004) (215)
Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis (2011) (210)
Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients (2007) (209)
Mechanisms of action of intravenous immune globulin in immune‐mediated diseases (1996) (204)
Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. (2008) (204)
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial (2021) (195)
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2) (2018) (192)
Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. (2009) (192)
Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. (2007) (191)
Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus (2001) (189)
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial (2020) (188)
The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. (2009) (187)
Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies (2017) (187)
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies (2022) (185)
Geoepidemiology of systemic sclerosis. (2010) (181)
Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study (2008) (179)
Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. (1995) (177)
Brief Communication: Case Reports of Ribavirin Treatment for Chronic Hepatitis E (2010) (177)
Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. (2008) (171)
Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. (2013) (169)
Selective Oxidation of DNA Topoisomerase 1 Induces Systemic Sclerosis in the Mouse1 (2009) (169)
Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. (2012) (168)
Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension (2005) (167)
Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. (2011) (166)
Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. (2006) (166)
Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. (2012) (161)
Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. (2012) (161)
Systemic sclerosis-associated pulmonary arterial hypertension. (2010) (156)
STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. (2009) (156)
New insights into the pathogenesis of systemic sclerosis. (2003) (155)
Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. (2012) (155)
Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). (2016) (154)
Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. (2004) (153)
Prevalence of systemic sclerosis in a French multi-ethnic county. (2004) (150)
Renal complications and scleroderma renal crisis. (2006) (144)
Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients (2008) (143)
Proliferating cell nuclear antigen acts as a cytoplasmic platform controlling human neutrophil survival (2010) (142)
European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes (2017) (141)
Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). (2014) (138)
Analysis of the normal human IgG antibody repertoire. Evidence that IgG autoantibodies of healthy adults recognize a limited and conserved set of protein antigens in homologous tissues. (1995) (137)
Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty‐Five Years or Older: Results of a Multicenter, Open‐Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide–Based Induction Therapy (2015) (137)
Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. (2007) (136)
Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis (2009) (135)
Intravenous immunoglobulins for steroid‐refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients (2010) (132)
Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension (2006) (131)
Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? (2013) (131)
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. (2008) (130)
Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era (2012) (130)
Clinical applications of intravenous immunoglobulins (IVIg) – beyond immunodeficiencies and neurology (2009) (125)
Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. (2013) (123)
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population (2010) (122)
Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study (2015) (122)
Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. (2007) (121)
Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. (2012) (121)
Autoimmune manifestations in primary immune deficiencies. (2009) (121)
Pathogenesis of giant cell arteritis: More than just an inflammatory condition? (2010) (118)
The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty‐Seven Patients (2015) (117)
Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome. (2017) (116)
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides (2018) (116)
Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. (2003) (114)
Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale (2007) (114)
Interstitial Lung Disease in Anti–Jo‐1 Patients With Antisynthetase Syndrome (2013) (114)
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. (2009) (113)
Long‐Term Outcomes Among Participants in the WEGENT Trial of Remission‐Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis (2016) (111)
Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. (2008) (111)
Analysis of the natural human IgG antibody repertoire: life‐long stability of reactivities towards self antigens contrasts with age‐dependent diversification of reactivities against bacterial antigens (1995) (111)
The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. (2008) (110)
Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. (2015) (108)
Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. (2002) (107)
Microscopic polyangiitis and polyarteritis nodosa: how and when do they start? (2003) (106)
The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context (2013) (101)
Adding Azathioprine to Remission‐Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors (2017) (100)
Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP) (2006) (100)
The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension (2013) (98)
Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers (2011) (97)
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) (2017) (97)
Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis (2007) (97)
The Self‐Reactive Antibody Repertoire of Normal Human Serum IgM is Acquired in Early Childhood and Remains Conserved Throughout Life (1996) (96)
Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature (2019) (95)
Scleroderma Renal Crisis: A Rare but Severe Complication of Systemic Sclerosis (2011) (92)
Systemic sclerosis: state of the art on clinical practice guidelines (2018) (91)
Severe Perturbations of the Blood T Cell Repertoire in Polymyositis, But Not Dermatomyositis Patients1 (2001) (90)
Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma (2011) (90)
Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. (2017) (88)
Long‐term outcome of patients with polymyositis/ dermatomyositis and anti‐PM‐Scl antibody (2010) (86)
Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. (2015) (86)
Granulomatosis-associated common variable immunodeficiency disorder: a case–control study versus sarcoidosis (2012) (86)
Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. (2011) (85)
Rituximab Maintenance Therapy for Granulomatosis with Polyangiitis and Microscopic Polyangiitis (2012) (85)
Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. (2011) (85)
NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis (2010) (85)
A descriptive and prognostic study of systemic sclerosis-associated myopathies (2008) (84)
Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis. (2015) (81)
Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. (2013) (77)
[Interstitial lung disease in systemic sclerosis]. (2007) (77)
Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. (2003) (76)
Sjogren's syndrome is associated with and not secondary to systemic sclerosis. (2006) (76)
Anti‐IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss): Data on Seventeen Patients (2016) (76)
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers (2021) (76)
Is pulmonary arterial hypertension really a late complication of systemic sclerosis? (2009) (75)
Mechanisms of action of intravenous immunoglobulin. (2017) (75)
Systemic Sclerosis‐Associated Myopathy (2007) (75)
The telomere/telomerase system in autoimmune and systemic immune-mediated diseases. (2010) (74)
Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ) (2005) (74)
Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. (2014) (73)
Mood and anxiety disorders in systemic sclerosis patients. (2011) (73)
Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. (2005) (72)
Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. (2002) (70)
Tumor necrosis factor-alpha blockade and the risk of vasculitis. (2004) (70)
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2020) (68)
Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. (1992) (68)
TNF alpha antagonist therapy and safety monitoring. (2011) (68)
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide (2007) (68)
Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. (2011) (68)
Recommendations for the care of oral involvement in patients with systemic sclerosis (2011) (68)
Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. (2014) (67)
Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease (2006) (66)
Therapy of polymyositis and dermatomyositis. (2011) (66)
Stability of Natural Self-Reactive Antibody Repertoires During Aging (2004) (66)
Myopathies related to systemic sclerosis: a case–control study of associated clinical and immunological features (2010) (65)
Phenotype-Haplotype Correlation of IRF5 in Systemic Sclerosis: Role of 2 Haplotypes in Disease Severity (2010) (64)
Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. (2011) (64)
Antiendothelial Cells Autoantibodies in Vasculitis-Associated Systemic Diseases (2008) (64)
Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. (2010) (63)
Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. (2007) (63)
Analysis of human self-reactive antibody repertoires by quantitative immunoblotting. (2000) (63)
Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature. (2017) (62)
Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis (2014) (61)
Pulmonary arterial hypertension: an autoimmune disease? (2005) (61)
Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. (2012) (61)
Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? (2007) (61)
Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients. (2009) (60)
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis (2019) (59)
Scleroderma Renal Crisis (2014) (59)
Proteinase 3, the Autoantigen in Granulomatosis with Polyangiitis, Associates with Calreticulin on Apoptotic Neutrophils, Impairs Macrophage Phagocytosis, and Promotes Inflammation (2012) (59)
Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A French Nationwide Study of Ninety‐Two Patients (2015) (59)
Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. (2011) (59)
Pathophysiology of systemic sclerosis: state of the art in 2014. (2014) (58)
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. (2017) (58)
Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. (2006) (57)
Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. (2011) (56)
Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis (2016) (56)
Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. (2013) (55)
Patient preference disability questionnaire in systemic sclerosis: a cross-sectional survey. (2008) (55)
Endothelin-1 expression in scleroderma renal crisis. (2011) (54)
Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach (2011) (53)
Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor (2011) (53)
Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. (2007) (53)
IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients. (2004) (53)
Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry (2018) (53)
Rituximab (MabThera) therapy and safety management. Clinical tool guide. (2008) (53)
Antifibroblast antibodies from systemic sclerosis patients bind to α-enolase and are associated with interstitial lung disease (2009) (53)
Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. (2015) (52)
Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. (2011) (52)
Interaction of proteinase 3 with its associated partners: implications in the pathogenesis of Wegener's granulomatosis (2010) (52)
Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease (2012) (51)
Altered control of self-reactive IgG by autologous IgM in patients with warm autoimmune hemolytic anemia. (2000) (51)
C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysis. (2011) (51)
Polyarteritis Nodosa and Churg-Strauss Angiitis: Characteristics and Outcome in 38 Patients over 65 Years (2002) (51)
Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial (2017) (51)
Scleroderma Peripheral B Lymphocytes Secrete Interleukin‐6 and Transforming Growth Factor β and Activate Fibroblasts (2017) (51)
Systemic Vasculitis During the Course of Systemic Sclerosis (2013) (50)
Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial (2010) (50)
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. (2015) (50)
Impact of pain in health related quality of life of patients with systemic sclerosis. (2006) (50)
Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension (2018) (50)
Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. (2010) (49)
New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). (2012) (48)
Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients (2016) (48)
Association of Gender with Clinical Expression, Quality of Life, Disability, and Depression and Anxiety in Patients with Systemic Sclerosis (2011) (48)
Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired membrane expression of the chemokine receptor CXCR4. (2010) (48)
In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations (2013) (47)
Outcomes in critically ill patients with systemic rheumatic disease: a multicenter study. (2015) (47)
Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immune‐Mediated Inflammatory Diseases (2013) (46)
Acquired C1-Inhibitor Deficiency: 7 Patients Treated with Rituximab (2012) (46)
Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. (2014) (46)
Immunoglobulins and the regulation of autoimmunity through the immune network. (1996) (45)
Brief Report: Childhood‐Onset Systemic Necrotizing Vasculitides: Long‐Term Data From the French Vasculitis Study Group Registry (2015) (45)
Identification of target antigens of antiendothelial cell antibodies in healthy individuals: A proteomic approach (2008) (45)
Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study (2017) (44)
Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. (2012) (44)
Clinical, Functional and Health-Related Quality of Life Correlates of Clinically Significant Symptoms of Anxiety and Depression in Patients with Systemic Sclerosis: A Cross-Sectional Survey (2014) (44)
Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study (2018) (44)
Interstitial lung disease in systemic sclerosis. (2011) (43)
Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. (2014) (43)
IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction (2011) (43)
Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). (2006) (43)
A Mimic of p21WAF1/CIP1 Ameliorates Murine Lupus1 (2005) (43)
Natural anti-endothelial cell antibodies. (2008) (42)
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population (2006) (41)
Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (2017) (41)
Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. (1994) (41)
European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis (2017) (41)
Sarcoidosis Occurring After Lymphoma (2014) (41)
Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. (2012) (41)
Relevance of diagnostic investigations in patients with uveitis: Retrospective cohort study on 300 patients. (2017) (40)
Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases (2007) (40)
Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? (2011) (40)
[Interstitial lung disease in connective tissue disorders]. (2005) (40)
Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case-control study from the French Vasculitis Study Group Registry. (2017) (40)
Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases. (2013) (39)
Natural and disease associated anti-myeloperoxidase (MPO) autoantibodies. (2008) (37)
Independent Replication and Metaanalysis of Association Studies Establish TNFSF4 as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis (2012) (37)
Antiphospholipid syndrome: state of the art on clinical practice guidelines (2018) (37)
The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis (2010) (37)
Patients’ views and needs about systemic sclerosis and its management: a qualitative interview study (2017) (37)
The Scleroderma Kidney: Progress in Risk Factors, Therapy, and Prevention (2011) (36)
Risk of scleroderma according to the type of immune checkpoint inhibitors. (2020) (36)
Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome. (1999) (36)
Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. (2004) (36)
Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. (2015) (36)
Intravenous immunoglobulins in infectious diseases: where do we stand? (2003) (36)
Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. (2010) (35)
Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients (2014) (35)
[Bosentan for treatment of active digital ulcers in patients with systemic sclerosis]. (2006) (35)
Employment status and socio-economic burden in systemic sclerosis: a cross-sectional survey. (2010) (35)
Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. (2019) (34)
The economic burden and health-related quality of life associated with systemic sclerosis in France (2015) (34)
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial (2020) (33)
IgM and IgG autoantibodies from microscopic polyangiitis patients but not those with other small- and medium-sized vessel vasculitides recognize multiple endothelial cell antigens. (2003) (33)
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis (2020) (33)
Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience. (2015) (33)
The Advantage of Specific Intravenous Immunoglobulin (sIVIG) on Regular IVIG: Experience of the Last Decade (2012) (33)
Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology (2019) (33)
Serum Eosinophil Cationic Protein (2007) (32)
Idiopathic CD 4 Lymphocytopenia Clinical and Immunologic Characteristics and Follow-Up of 40 Patients (2014) (32)
Basophils and nephritis in lupus. (2010) (32)
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients (2022) (32)
Validation of the Self‐Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient‐Centered Intervention Network Cohort Study (2016) (32)
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts (2018) (32)
Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. (2019) (32)
There is a need for new systemic sclerosis subset criteria. A content analytic approach (2018) (32)
Idiopathic CD4 Lymphocytopenia (2014) (31)
Identification of target antigens of self‐reactive IgG in intravenous immunoglobulin preparations (2009) (31)
Sjögren’s syndrome: state of the art on clinical practice guidelines (2018) (31)
Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients (2019) (31)
Anti-endothelial cell antibodies in vasculitis: A systematic review. (2017) (31)
Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study (2007) (31)
Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. (2015) (31)
Increased membrane expression of proteinase 3 during neutrophil adhesion in the presence of anti proteinase 3 antibodies. (2007) (31)
Interstitial Lung Disease Associated with Systemic Sclerosis (2007) (31)
mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G (2018) (30)
Patients' beliefs about the causes of systemic lupus erythematosus. (2010) (30)
Incidence, risk factors, and mortality of neonatal and late-onset dilated cardiomyopathy associated with cardiac neonatal lupus. (2017) (30)
Association of hypoxia‐inducible factor 1A (HIF1A) gene polymorphisms with systemic sclerosis in a French European Caucasian population (2009) (29)
DUSP4-mediated accelerated T-cell senescence in idiopathic CD4 lymphopenia. (2015) (29)
Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality. (2019) (28)
Levamisole-induced vasculopathy: A systematic review. (2019) (28)
Anti-annexin V antibodies: are they prothrombotic? (2005) (28)
Proteomes of umbilical vein and microvascular endothelial cells reflect distinct biological properties and influence immune recognition (2012) (28)
Localized neurological necrotizing vasculitides. Three cases with isolated mononeuritis multiplex. (2001) (28)
Polyreactive Autoantibodies Purified from Human Intravenous Immunoglobulins Prevent the Development of Experimental Autoimmune Diseases (2003) (28)
Scleroderma Renal Crisis, Still a Life‐Threatening Complication (2007) (28)
Clinical and pathological significance of cutaneous manifestations in ANCA-associated vasculitides. (2017) (27)
Therapeutic options for systemic sclerosis related interstitial lung diseases. (2010) (27)
Sensitivity to Change in Systemic Sclerosis of the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (MACTAR): Shift in Patient Priorities Over Time (2010) (27)
Cardiac magnetic resonance imaging in Churg-Strauss-syndrome. Impact of immunosuppressants on outcome assessed in a prospective study on 8 patients. (2010) (27)
Pre-test probability for SARS-Cov-2-related infection score: The PARIS score (2020) (27)
Intravenous Immunoglobulin Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B 19 Infection : A Retrospective Study of 10 Patients and Review of the Literature (2013) (27)
Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation. (2017) (26)
Postrehabilitation Functional Improvements in Patients With Inflammatory Myopathies: The Results of a Randomized Controlled Trial. (2017) (26)
Identification of target antigens of anti-endothelial cell antibodies in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides: a proteomic approach. (2014) (26)
Cerebral Vasculopathy Is Associated with Severe Vascular Manifestations in Systemic Sclerosis (2009) (26)
Concomitant polymyositis and myasthenia gravis reveal malignant thymoma. A case report and review of the literature. (1999) (26)
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases (2022) (25)
The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET (2021) (25)
Association Study of ITGAM, ITGAX, and CD58 Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts (2011) (25)
Analysis of antibody reactivities toward self antigens of IgM of patients with Waldenström's macroglobulinemia. (1997) (25)
Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (MAINRITSAN): Follow-up at 34 months (2013) (25)
Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies. (2022) (25)
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients (2013) (25)
Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement. (2007) (24)
Dividing the Janus vasculitis? Pathophysiology of eosinophilic granulomatosis with polyangitis. (2016) (24)
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial (2021) (24)
Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study (2020) (23)
Hydroxyethyl starch-induced renal insufficiency after plasma exchange in a patient with polymyositis and liver cirrhosis. (2001) (23)
Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes (2016) (23)
Abatacept therapy and safety management. (2012) (23)
Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. (2019) (23)
Undifferentiated connective tissue disease: state of the art on clinical practice guidelines (2019) (23)
Orientation diagnostique devant une lymphopénie (2006) (22)
Pulmonary arterial hypertension in idiopathic inflammatory myopathies (2016) (22)
Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases (2006) (22)
Lack of association between B19 or V9 erythrovirus infection and ANCA-positive vasculitides: a case-control study. (2003) (22)
A Combined SDS‐PAGE and Proteomics Approach to Identify Target Autoantigens in Healthy Individuals and Patients with Autoimmune Diseases (2007) (22)
Tracheobronchial involvement of relapsing polychondritis. (2019) (22)
Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases (2015) (21)
Physical and occupational therapy referral and use among systemic sclerosis patients with impaired hand function: results from a Canadian national survey. (2012) (21)
Scleroderma Renal Crisis. (2015) (21)
Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling (2014) (21)
IgG4-related diseases: state of the art on clinical practice guidelines (2019) (21)
Systemic small sized vessel vasculitis after massive antigen inhalation. (2001) (21)
Instability of Natural Antibody Repertoires in Systemic Lupus Erythematosus Patients, Revealed by Multiparametric Analysis of Serum Antibody Reactivities (1997) (21)
Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. (2016) (21)
Factors Associated with Major Cardiovascular Events in Patients with Systemic Necrotizing Vasculitides: Results of a Longterm Followup Study (2014) (21)
Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients. (2018) (21)
Deep Learning-based Approach for Automated Assessment of Interstitial Lung Disease in Systemic Sclerosis on CT Images. (2020) (21)
Contribution of antiferritin antibodies to diagnosis of giant cell arteritis (2013) (20)
[Systemic sclerosis: pathophysiology of a multifaceted disease]. (2006) (20)
Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. (2016) (20)
Proteomic analysis of neutrophils in ANCA-associated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1 involved in apoptotic cell clearance. (2019) (20)
Selective impairment of serum antibody repertoires toward muscle and thymus antigens in patients with seronegative and seropositive myasthenia gravis (1998) (20)
Long-term outcome of children with pediatric-onset cutaneous and visceral polyarteritis nodosa. (2015) (20)
Using Optimal Test Assembly Methods for Shortening Patient‐Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale‐6: A Scleroderma Patient‐Centered Intervention Network Cohort Study (2016) (19)
French recommendations for the management of systemic sclerosis (2021) (19)
Subacute Cutaneous Lupus Erythematosus Induced and Exacerbated by Proton Pump Inhibitors (2013) (19)
Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort (2011) (19)
Medical cure of plasma cell granuloma of the thyroid associated with Hashimoto's thyroiditis: a case report and review. (2004) (19)
Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. (2020) (19)
Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. (2017) (19)
Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study (2018) (19)
Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients (2020) (18)
[Immunomodulatory effects of intravenous immunoglobulins]. (2000) (18)
Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care. (2019) (18)
Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis (2020) (18)
A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension (2015) (18)
Elastic Registration-driven Deep Learning for Longitudinal Assessment of Systemic Sclerosis Interstitial Lung Disease at CT. (2020) (18)
Hepatitis B virus-related polyarteritis nodosa and membranous nephropathy. (1995) (18)
Characteristics of Vogt-Koyanagi-Harada Disease in a French Cohort: Ethnicity, Systemic Manifestations, and HLA Genotype Data (2008) (18)
Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor β pathway in patients with systemic sclerosis (2011) (18)
Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysis (2020) (18)
Successful treatment of thymoma‐associated pure red cell aplasia with intravenous immunoglobulins (2000) (18)
Pneumococcal and influenza vaccination rates in patients treated with corticosteroids and/or immunosuppressive therapies for systemic autoimmune diseases: A cross-sectional study. (2017) (18)
Translation, cross-cultural adaptation, and validation of the Mouth Handicap in Systemic Sclerosis questionnaire (MHISS) into the Dutch language (2013) (18)
Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients. (2019) (18)
High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance (2017) (17)
Immune modulating effects of intravenous immunoglobulin (IVIg) in autoimmune diseases. (1994) (17)
Cardiac Intravoxel Incoherent Motion Diffusion‐Weighted Magnetic Resonance Imaging With T1 Mapping to Assess Myocardial Perfusion and Fibrosis in Systemic Sclerosis: Association With Cardiac Events From a Prospective Cohort Study (2020) (17)
Patients', relatives', and practitioners' views of pulmonary arterial hypertension: A qualitative study. (2016) (17)
Low influenza vaccination rate among patients with systemic sclerosis. (2010) (17)
Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines (2019) (16)
IgA glomerulonephritis associated with microscopic polyangiitis or Churg-Strauss syndrome. (1999) (16)
Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease (2016) (16)
Validation of the COVID-19 Fears Questionnaires for Chronic Medical Conditions: A Scleroderma Patient-centered Intervention Network COVID-19 Cohort study (2020) (16)
Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. (2008) (16)
Association study of B-cell marker gene polymorphisms in European Caucasian patients with systemic sclerosis. (2011) (16)
[Pathogenesis of systemic scleroderma: immunological aspects]. (2002) (16)
Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Case–Control Study (2020) (16)
Altered Responses to Homeostatic Cytokines in Patients with Idiopathic CD4 Lymphocytopenia (2013) (16)
Outcome of Patients with Systemic Sclerosis in the Intensive Care Unit (2015) (16)
Granulomatosis with polyangiitis according to geographic origin and ethnicity: clinical-biological presentation and outcome in a French population (2016) (16)
Systemic sclerosis: Sexual dysfunction and lower urinary tract symptoms in 73 patients. (2016) (16)
Is there today a place for corticosteroids in the treatment of scleroderma? (2019) (16)
[Diagnosis of lymphocytopenia]. (2006) (15)
Treatment of systemic necrotizing vasculitides in patients ≥ 65 years old: Results of the multicenter randomized CORTAGE trial (2013) (15)
Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. (2019) (15)
Analysis of autoantibody repertoires in small- and medium-sized vessels vasculitides. Evidence for specific perturbations in polyarteritis nodosa, microscopic polyangiitis, Churg-Strauss syndrome and Wegener's granulomatosis. (2005) (15)
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). (2020) (14)
Changes over Time and Responsiveness of the Cochin Hand Function Scale and Mouth Handicap in Systemic Sclerosis Scale in Patients with Systemic Sclerosis: A Prospective Observational Study (2016) (14)
Management of secondary immune deficiencies: what is the role of immunoglobulins? (2013) (14)
Novelties in the field of autoimmunity - 1st Saint Petersburg congress of autoimmunity, the bridge between east and west. (2017) (14)
Neutrophils and B lymphocytes in ANCA‐associated vasculitis (2009) (13)
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies (2022) (13)
Esophageal involvement as an initial manifestation of Churg-Strauss syndrome. (2007) (13)
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database (2020) (13)
Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study. (2014) (13)
Use of Elastic Registration in Pulmonary MRI for the Assessment of Pulmonary Fibrosis in Patients with Systemic Sclerosis. (2019) (13)
Severe COVID-19 is associated with hyperactivation of the alternative complement pathway (2021) (13)
Lymphoma complicating common variable immunodeficiency with granulomatous disease: report of two cases (2003) (13)
Radiological bone lesions in fibroblastic rheumatism; case report. (2007) (12)
Analysis of risk factors for complications and adverse obstetrical outcomes in women with Takayasu arteritis: a French retrospective study and literature review (2020) (12)
Association of Metalloproteinase Gene Polymorphisms with Systemic Sclerosis in the European Caucasian Population (2010) (12)
[Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis]. (2004) (12)
The association of sociodemographic and disease variables with hand function: a Scleroderma Patient-centered Intervention Network cohort study. (2018) (12)
Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU®) patient-reported outcome instrument (2020) (12)
[Treatment of systemic autoimmune and inflammatory diseases with rituximab]. (2009) (12)
Effect of plasma exchange in acute respiratory failure due to Anti-neutrophil cytoplasmic antibody-associated vasculitis (2018) (12)
Childhood- versus Adult-Onset Polyarteritis Nodosa Results from the French Vasculitis Study Group Registry. (2018) (12)
Angiotensin-Converting Enzyme Gene Does Not Contribute to Genetic Susceptibility to Systemic Sclerosis in European Caucasians (2009) (12)
[Lymphocytopenia: aetiology and diagnosis, when to think about idiopathic CD4(+) lymphocytopenia?]. (2012) (12)
Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. (2021) (12)
Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval (2014) (12)
Differences in patients with systemic sclerosis recruited from associations and tertiary care settings. (2010) (11)
IMMUNOMODULATION OF AUTOIMMUNE AND SYSTEMIC INFLAMMATORY DISEASES WITH INTRAVENOUS IMMUNOGLOBULIN (1994) (11)
Mechanisms of Intravenous Immunoglobulin Action in the Treatment of Autoimmune Disorders (2012) (11)
Localized subcutaneous Nocardia farcinica abscess in a woman with overlap syndrome between systemic scleroderma and polymyositis. (1999) (11)
Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease (2005) (11)
Factors influencing influenza-vaccination in adults under immunosuppressive therapy for a systemic inflammatory disease. (2009) (10)
Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis. (2007) (10)
Severe mitral stenosis as the first manifestation of systemic lupus erythematosus in a 20-year-old woman: the value of magnetic resonance imaging in the diagnosis of Libman-Sacks endocarditis (2014) (10)
Antigen inhalation as a triggering factor in systemic small-sized-vessel vasculitis. Four cases. (2001) (10)
Treating systemic sclerosis in 2001. (2001) (10)
Association Study of Serotonin Transporter Gene (SLC6A4) in Systemic Sclerosis in European Caucasian Populations (2010) (10)
Transgenic Mice Expressing Human Proteinase 3 Exhibit Sustained Neutrophil-Associated Peritonitis (2017) (10)
OP0213 Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (MAINRITSAN): Follow Up at 34 Months (2013) (10)
Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody–associated Vasculitis-related Bronchiectasis: Data from 61 Patients (2019) (10)
IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts (2008) (10)
Interferon‐α in corticosteroid‐resistant asthma and Churg–Strauss syndrome (2003) (10)
Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial (2021) (10)
Extra-haematological manifestations related to human parvovirus B19 infection: retrospective study in 25 adults (2018) (10)
Association study of 3 rheumatoid arthritis risk loci in systemic sclerosis in European Caucasian population. (2011) (10)
Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group. (2019) (9)
Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence (2020) (9)
[Renal involvement in patients with systemic sclerosis]. (2006) (9)
Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19 (2021) (9)
Brachial plexopathy associated with diffuse edematous scleroderma. (2000) (9)
Clinical characteristics and persistence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in 4,607 French healthcare workers: Comparison with European countries (2020) (9)
Antitopoisomerase 1 Antibodies in Systemic Sclerosis (2007) (9)
[Hand involvement in systemic sclerosis]. (2013) (9)
Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnesses. (2011) (9)
Polyarteritis nodosa and mixed cryoglobulinaemia related to hepatitis B and C virus coinfection (2001) (9)
Candidate Gene Study in Systemic Sclerosis Identifies a Rare and Functional Variant of the TNFAIP 3 Locus as a Risk Factor for Polyautoimmunity (2012) (9)
Testing for levamisole and cocaine in hair samples for the diagnosis of levamisole‐related panniculitis (2015) (9)
Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study. (2020) (9)
Intraabdominal macrocystic lymphatic malformation (lymphangioma) infected with Salmonella enteritidis: case report and review. (1997) (9)
SSc in 2011: From mechanisms to medicines (2012) (9)
[Eosinophil granule cationic proteins: eosinophil activation markers]. (2006) (9)
Osteomalacia revealing celiac disease and primary biliary cirrhosis-related Fanconi syndrome in a patient with systemic sclerosis. (2008) (9)
VANCOMYCIN-RESISTANT ENTEROCOCCI AND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS : THE GRAM-POSITIVE CHALLENGES (1996) (8)
Tobacco differentially affects the clinical-biological phenotypes of ANCA-associated vasculitides. (2015) (8)
Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND): Study protocol (2018) (8)
Antisignal recognition particle antibodies-related cardiomyopathy. (2013) (8)
Corrigendum to “Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named churg–strauss syndrome)” [Journal of Autoimmunity 48–49 (2014) 99–103] (2014) (8)
Computed Tomography Findings Of Pulmonary Veno-Occlusive Disease In Scleroderma Patients Presenting With Precapillary Pulmonary Hypertension (2012) (8)
Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function. (2017) (8)
Serum 1,25(OH)2 Vitamin D and 25(OH) Vitamin D Ratio for the Diagnosis of Sarcoidosis-Related Uveitis (2018) (8)
Treatment of Syphilis-Associated Cerebral Vasculitis: Reappearance of an Old Question. (2018) (8)
[Infectious complications of systemic sclerosis]. (2009) (8)
[Pathogenesis of primary systemic vasculitides (II): ANCA-negative vasculitides]. (2005) (8)
Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study (2019) (8)
Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients (2020) (8)
Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients (2021) (8)
Survival Improved in Patients Aged ≤ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France (2020) (8)
Carotid artery intima–media thickness, heat shock proteins and oxidized LDL autoantibodies in systemic necrotizing vasculitis (2008) (7)
Efficacy of baricitinib for refractory large vessel vasculitis. (2021) (7)
Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry (2022) (7)
The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial (2019) (7)
Ocular safety profile of BRAF and MEK inhibitors: data from the World Health Organization Pharmacovigilance Database. (2021) (7)
Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. (2020) (7)
Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study (2020) (7)
Morphoea (localized scleroderma): baseline body surface involvement and antinuclear antibody may have a prognostic value (2009) (7)
Role of B-Cell in the Pathogenesis of Systemic Sclerosis (2022) (7)
Pathophysiology of systemic sclerosis. (2021) (7)
Construction of an ICF core set and ICF-based questionnaire assessing activities and participation in patients with systemic sclerosis. (2019) (7)
Systemic scleroderma associated with bilateral ulnar nerve entrapment at the elbow. (2000) (7)
Development of a new patient‐reported outcome measure to assess activities and participation in people with systemic sclerosis: the Cochin 17‐item Scleroderma Functional scale (2020) (7)
Revisiting characteristics, treatment and outcome of cardiomyopathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). (2021) (7)
[Pathogenesis of primary systemic vasculitides (I): ANCA-positive vasculitides]. (2005) (7)
Myeloproliferative neoplasms and clonal hematopoiesis in patients with giant cell arteritis: a case-control and exploratory study. (2021) (7)
Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA), polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) with no initial Five-Factor Score-defined poor-prognosis factors (FFS = 0): Baseline factors associated with cytotoxic agent and immunomodulator prescription (2013) (6)
Analysis of self-reactive antibody repertoires in normal pregnancy. (1998) (6)
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study (2022) (6)
[Dyspnea upon exertion in systemic scleroderma: from symptom to etiological diagnosis]. (2009) (6)
Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-related Uveitis (2019) (6)
An immunohistochemical analysis of fibroblasts in giant cell arteritis. (2021) (6)
Vascularites pulmonaires: le point de vue du pathologiste. (2000) (6)
[Treatment of severe Behçet's disease with anti-TNF-alpha: infliximab. A case report]. (2002) (6)
Selective impairment of serum antibody repertoires toward muscle and thymus antigens in patients with seropositive and seronegative myasthenia gravis (1997) (6)
[Psychiatric manifestations of systemic sclerosis]. (2002) (6)
[Antileukotrienes and Churg-Strauss syndrome]. (2007) (6)
Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient‐Centered Intervention Network Cohort Study (2021) (6)
[Intravenous immunoglobulins in autoimmune and inflammatory disorders: beyond a simple substitution]. (2009) (6)
Immunizations in Adult Patients with Systemic Sclerosis (2009) (6)
Skin necrosis revealing antiphospholipid syndrome during immunotherapy for melanoma. (2010) (6)
Telangiectasic mastocytosis with systemic sclerosis. (2013) (6)
Interferon-alpha in corticosteroid-resistant asthma and Churg-Strauss syndrome. (2003) (6)
[Therapeutic management of systemic sclerosis]. (2006) (6)
A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects. (2021) (6)
Recurrent acute pericarditis in Takayasu arteritis. (2013) (5)
A role for IL-33–activated ILC2s in eosinophilic vasculitis (2021) (5)
Ethnic influence on the phenotype of French patients with systemic sclerosis. (2020) (5)
Aortic thrombosis in young women with Crohn's disease receiving adalimumab: report of two cases. (2011) (5)
Handgrip strength is a comorbidity marker in systemic necrotizing vasculitides and predicts the risk of fracture and serious adverse events. (2020) (5)
Skewed peripheral B- and T-cell compartments in patients with ANCA-associated vasculitis. (2020) (5)
[Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases]. (2009) (5)
[Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases]. (1999) (5)
Rituximab as first‐line therapy for acquired haemophilia A: a single‐centre 10‐year experience (2016) (5)
Favorable outcome of gemcitabine-induced respiratory distress syndrome. (2000) (5)
Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor‐ß (2018) (5)
Workload, well-being and career satisfaction among French internal medicine physicians and residents in 2018 (2019) (5)
[Pathophysiology of ANCA-associated vasculitides]. (2012) (5)
[Periarteritis nodosa induced by hepatitis B virus]. (1999) (5)
[Causes and mechanisms of systemic vasculitides]. (2008) (5)
[Digital ulcers in systemic scleroderma]. (2011) (5)
[Management of digital ulcers from systemic scleroderma]. (2008) (5)
[Idiopathic retroperitoneal fibrosis: a multicentric retrospective study of 30 French cases and follow-up of the renal function]. (2014) (5)
Efficacy and safety of treatments in cutaneous polyarteritis nodosa: a French observational retrospective study. (2021) (5)
Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2022) (5)
The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. (2022) (5)
Survival improved in systemic sclerosis associated pulmonary arterial hypertension patients aged 70 years or less over the period 2006-2017 in France. (2019) (5)
[Valvular locations in Whipple's disease: report of two cases and review of the literature]. (2001) (4)
Drug-induced eosinophilic fasciitis: a dual pharmacovigilance analysis. (2021) (4)
Autoantibodies versus Skin Fibrosis Extent in Systemic Sclerosis: A Case-Control Study of Inverted Phenotypes (2022) (4)
Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry (2021) (4)
Quality of Life in Systemic Sclerosis (2010) (4)
Altered salivary redox homeostasis in patients with systemic sclerosis (2006) (4)
Localised Versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry. (2021) (4)
Development and validation of a patient‐reported outcome in systemic sclerosis: the Hand scleroDerma lived Experience (HAnDE) scale * (2021) (4)
A Mimic of p21 WAF1/CIP1 Ameliorates Murine Lupus 1 (2005) (4)
[Relapsing polychondritis: What's new in 2017?] (2018) (4)
Iconography : Bosentan for treatment of active digital ulcers in patients with systemic sclerosis (9 cases) (2008) (4)
[Investigation of the complement system in clinical practice]. (2003) (4)
Epidemiology, Environmental, and Infectious Risk Factors (2017) (4)
[Indications and mechanisms of action of the intravenous immunoglobulines in the systemic autoimmune and inflammatory pathologies]. (2009) (4)
Mental health before and during the pandemic in people with systemic sclerosis (2021) (4)
Presentation, Diagnosis and Management of Subglottic and Tracheal Stenosis During Systemic Inflammatory Diseases. (2021) (4)
[Neuropsychiatric manifestations in systemic sclerosis]. (2010) (4)
Risk of malignancy in patients treated for systemic necrotising vasculitis (2019) (4)
Risk of infection in systemic diseases. (2009) (4)
A Mimic of p21 Ameliorates Murine Lupus (2005) (4)
Costs of intravenous immunoglobulin therapy in patients with unconfirmed parvovirus b19 pure red cell aplasia. (2015) (4)
[Tuberculosis risk among patients with systemic diseases]. (2009) (4)
[Treatment of ANCA-positive systemic vasculitis with intravenous immunoglobins]. (1999) (4)
Atypical vasculitis mimicking chronic thromboembolic pulmonary hypertension. (2015) (4)
Vasculitis associated with familial Mediterranean fever: a study on 16 french adult cases (2015) (4)
Quantification of Antifibrillarin (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis (2021) (4)
015 Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis: data from 17 patients (2016) (4)
[2016 review on catastrophic antiphospholipid syndrome]. (2016) (3)
Treatment of Giant Cell Arteritis (GCA) (2022) (3)
The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial (2021) (3)
FRI0245 Survival and prognostic factors in patients with incident systemic sclerosis-associated pulmonary arterial hypertension from the french registry (2011) (3)
Aortic angiosarcoma masquerading as inflammatory aortitis. (2019) (3)
264. OCULAR INVOLVEMENT IN GRANULOMATOSIS WITH POLYANGIITIS: A SINGLE-CENTER COHORT STUDY ON 63 PATIENTS (2019) (3)
Treatment of systemic sclerosis. (2021) (3)
[Intravenous immunoglobulins: anti-infection indications]. (2000) (3)
Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? (2013) (3)
[Immunomodulatory effects of intravenous immunoglobulins]. (2004) (3)
Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program (2022) (3)
[Intravenous immunoglobulins: therapeutic indications]. (2005) (3)
[Immunoglobulins and physiopathology: actual indications]. (2007) (3)
[Professional consequences of systemic sclerosis]. (2013) (3)
[Pathophysiology of eosinophilic granulomatosis with polyangitis (Churg-Strauss)]. (2016) (3)
Indications for biotherapy in systemic vasculitides (2007) (3)
[Late onset of primary immune deficiencies]. (2010) (3)
Autoantibodies in Therapeutic Preparations of Human IgG (IVIg) (1996) (3)
Effects of non-pharmacological and non-surgical interventions on health outcomes in systemic sclerosis: protocol for a living systematic review (2021) (3)
IgA monoclonal gammopathy associated with refractory IgA vasculitis successfully treated with clone-targeted therapy. (2020) (3)
Inﬂammation, Growth Factors, and Pulmonary Vascular Remodeling (2016) (3)
[Systemic sclerosis: from physiopathology to treatment]. (2007) (3)
Free prednisolone pharmacokinetics predicted from total concentrations in patients with inflammatory – immunonologic conditions (2020) (3)
[Physiopathology of giant cell arteritis: From inflammation to vascular remodeling]. (2019) (3)
Ophthalmic involvement of chronic lymphocytic leukemia: a systematic review of 123 cases. (2020) (3)
Association study of CRP gene in systemic sclerosis in European Caucasian population (2014) (3)
Giardia lamblia infection in a patient with myotonic dystrophy. (2002) (3)
High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications (2020) (3)
Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study (2019) (3)
Whole blood gene expression profiling distinguishes systemic sclerosis‐overlap syndromes from other subsets (2020) (3)
Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study (2021) (3)
THU0237 Impact of recurrent ischemic digital ulcers on hand disability in systemic sclerosis – (2013) (2)
[The contribution of philosophy to immunology]. (2010) (2)
Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study (2022) (2)
Systemic sclerosis: views and thoughts for the future. (2014) (2)
Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis (2022) (2)
Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: place of rituximab and plasma exchange? (2022) (2)
[Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases]. (1993) (2)
[Systemic sclerosis associated pulmonary arterial hypertension: the pitfalls]. (2011) (2)
French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis (2021) (2)
Scleroderma cardiac crisis: A-life-threatening but reversible complication of systemic sclerosis. (2022) (2)
[Indications for intravenous immunoglobulins]. (2006) (2)
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort (2022) (2)
[Sjögren's syndrome and non-Hodgkin's lymphoma: from pathophysiology to treatment]. (2011) (2)
at proteins involved in the transforming growth factor beta pathway in patients with systemic sclerosis. (2011) (2)
Syndrome catastrophique des antiphospholipides (CAPS) : revue 2016 (2016) (2)
[Pulmonary arterial hypertension associated with connective tissue diseases]. (2014) (2)
Vitreous amyloidosis with autonomic neuropathy of the digestive tract associated with a novel transthyretin p.Gly87Arg variant in a Bangladeshi patient: a case report (2017) (2)
Role of therapeutic plasma exchanges in systemic vasculitis. (2020) (2)
Treatment of relapsing polychondritis: a systematic review. (2021) (2)
[Therapeutic indications of intravenous immunoglobulins]. (2003) (2)
Granulomatosis with Polyangiitis Sustained Remission Off-Therapy: Data from the French Vasculitis Study Group Registry. (2020) (2)
LB0002 Does Adding Azathioprine To Glucocorticoid Induction Increase The Remission Rate and Prevent Relapses in Patients with Systemic Necrotizing Vasculitides without Poor-Prognosis Factors? A Multicenter, Double-Blind Randomized Controlled Trial (2016) (2)
Breast adenocarcinoma complicating Kallmann's syndrome. (2001) (2)
Patients of 75 years and over with ANCA‐associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study (2021) (2)
[Biotherapies: toward a second revolution?]. (2009) (2)
[Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders]. (2007) (2)
[Necrotizing myopathy associated with anti-SRP auto-antibodies: transient efficacy of a therapeutic strategy associating plasma exchanges and rituximab]. (2012) (2)
A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency (2019) (2)
Celiprolol-induced lupus-like syndrome (2006) (2)
Abdominal adipose tissue predicts major cardiovascular events in systemic necrotising vasculitides. (2019) (2)
How to optimize the treatment of systemic vasculitides. (2000) (2)
Health Outcomes of 215 Mothers of Children With Autoimmune Congenital Heart Block: Analysis of the French Neonatal Lupus Syndrome Registry (2022) (2)
[Superficial porokeratosis of the lower limbs during systemic scleroderma]. (2009) (2)
[Severe cholestatic hepatitis revealing a DRESS syndrome]. (2013) (2)
Physiopathologie des vascularites ANCA-positives : acquisitions récentes (2003) (2)
Long-term outcomes of the WEGENT trial on remission-maintenance for granulomatosis with polyangiitis or microscopic polyangiitis (2019) (2)
OP0123 Prediction of progressive skin thickening in early diffuse systemic sclerosis using three-monthly skin scores from the european scleroderma observational study (ESOS) (2017) (2)
Reply to "Anti-endothelial cell antibodies in patients with AAV: the relationship with ANCA? Comment on: Identification of target antigens of anti-endothelial cell antibodies in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides: a proteomic approach" by Shen-Ju Gou, Ping Fu. (2014) (1)
Innate immunity and natural autoantibodies (2007) (1)
FRI0261 Observational Study of Outcome in Patients with Early Diffuse Cutaneous Systemic Sclerosis Treated with Immunosuppressive Therapies (ESOS Study) (2016) (1)
FRI0299 Pulmonary Arterial Hypertension in Idiopathic Inflammatory Myopathies: Data from The French Pulmonary Hypertension Registry and Review of The Literature (2016) (1)
[Severe respiratory syncytial virus pneumonia following bone marrow autograft. 3 cases]. (1992) (1)
355. FACTORS PREDICTING SEVERE INFECTIONS IN PATIENTS WITH SYSTEMIC NECROTIZING VASCULITIDES BASED ON DATA FROM 733 PATIENTS ENROLLED IN RANDOMIZED–CONTROLLED TRIALS (2019) (1)
Rare within rare. Necrotising scleritis and peripheral ulcerative keratitis: eye-threatening complications of relapsing polychondritis. (2021) (1)
Basic (PS01–PS58) (2012) (1)
The Clinical Spectrum and Outcome of Uveomeningitis: A Comprehensive Analysis of 110 Cases (2021) (1)
[Mandibular resorption, an underdiagnosed manifestation of systemic scleroderma]. (2006) (1)
[Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus]. (2013) (1)
Chronic Obstructive Pulmonary Disease Associated with Hypocomplementemic Urticarial Vasculitis. (2020) (1)
[Pansclerotic morphea with a rapidly fatal outcome in an 11-year-old girl]. (2016) (1)
Corrigendum to: Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients. (2022) (1)
Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. (2022) (1)
FRI0508 Analysis of risk factors of adverse obstetrical outcome in patients with takayasu arteritis (2018) (1)
Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND) (2022) (1)
[Humoral and cellular autoimmunity: from physiology to pathology]. (2009) (1)
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study (2022) (1)
Characteristics of patients with systemic sclerosis suffering from a lower limb amputation: Results of a French collaborative study (2020) (1)
Contribution of anti-ferritin antibodies to the diagnosis of giant cell arteritis (2013) (1)
Treatment of infections caused by highly resistant enterococci. (1997) (1)
L44. Management of relapses in vasculitis. (2013) (1)
[Heart involvement in systemic lupus erythematosus and antiphospholipid syndrome]. (2022) (1)
[Long-term treatments for systemic sclerosis: what are the perspectives?]. (2002) (1)
Comparison of Mental Health Symptoms Prior to and During COVID-19 among Patients with Systemic Sclerosis from Four Countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study (2020) (1)
[Diagnosis of primary immunodeficiency in adult patients]. (2006) (1)
Lymphoplasmacytic lymphoma associated with polyradiculoneuritis and cryoglobulinemia mimicking polyarteritis nodosa. (2007) (1)
AB0727 There is a Need for New Systemic Sclerosis Subset Criteria. A Content Analytic Approach (2015) (1)
[The reform of the third cycle of medical studies: What changes for internal medicine?] (2017) (1)
SAT0465 Construct Validity of the Promis-29 in Systemic Sclerosis: Preliminary Results from the Scleroderma Patient-Centered Intervention Network (Spin) Cohort (2015) (1)
Cluster analysis reveals eosinophilia and fibrosis as poor prognostic markers in 128 patients with eosinophilic fasciitis. (2022) (1)
Hypervirulent Klebsiella Pneumoniae, an Emerging Cause of Endogenous Endophthalmitis in A French Center: A Comparative Cohort Study. (2022) (1)
Remission and Low Disease Activity in Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual (2022) (1)
Primary and secondary glomerulonephritis I (2012) (1)
[Physiopathology of polymyositis and dermatomyositis, mechanism of action of intravenous immunoglobulins]. (2004) (1)
Determination of four homogeneous subgroups of patients with antiphospholipid syndrome: a cluster analysis based on 509 cases. (2022) (1)
[Eosinophilic pleural effusion associated to Churg and Strauss syndrome]. (2008) (1)
Extracorporeal photopheresis and cyclophosphamide for cancer-associated systemic sclerosis worsening induced by immune checkpoint inhibitors: a case report. (2022) (1)
[Pathogenesis of ANCA-positive vasculitides: recent advances]. (2003) (1)
Impact of air pollution on systemic sclerosis associated interstitial lung disease severity: a retrospective two-center cohort study (2022) (1)
THU0312 ADVENTITIAL FIBROBLAST, AN IMPORTANT PLAYER IN GIANT CELL ARTERITIS (2019) (0)
membrane expression of the chemokine receptor CXCR4 Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired (2013) (0)
[Benefits and risks of treatments used in systemic autoimmune diseases]. (2008) (0)
FRI0369 Neurotrophins are involved in vascular remodelling of giant cell arteritis. (2013) (0)
Sarcoidose et Oeil. SFO. pdf (2016) (0)
SP071ROLE OF COMPLEMENT IN SCLERODERMA RENAL CRISIS (2017) (0)
THU0316 Update on the juvenile systemic sclerosis inception cohort. www.juvenilescleroderma.com (2013) (0)
[Intravenous immunoglobulin therapy]. (2005) (0)
Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study. (2023) (0)
Presentation and management of granulomatosis with polyangiitis (Wegener’s) (GPA) central nervous system (CNS) involvement (2013) (0)
AB0439 Contribution of anti-ferritin antibodies to the diagnosis of giant cell arteritis (2013) (0)
Pregnancy and Scleroderma (2012) (0)
[Pulmonary vasculitis: histopathologic point of view]. (2000) (0)
Mise au point - Orientation diagnostique devant une lymphopénie (2008) (0)
patients, to systemic dissemination and the acute onset of systemic vasculitis progressive immune complex formation and deposition. (2001) (0)
Randomized controlled trial of an internet-based self-guided hand exercise program to improve hand function in people with systemic sclerosis: the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND) trial (2022) (0)
Clinico-radiological correlation and prognostic value of baseline chest computed tomography in eosinophilic granulomatosis with polyangiitis. (2023) (0)
Dr. Pène, et al reply (2016) (0)
Patient Acceptable Symptom State for Burden From Appearance Changes in People With Systemic Sclerosis: A Cross-sectional Survey (2022) (0)
OP0058 Efficacy of Sildenafil on Ischaemic Digital Ulcer Healing in Systemic Sclerosis: The Placebo-Controlled Seduce Study (2015) (0)
SAT0270 COMPREHENSIVE ICF CORE SET AND ICF-BASED QUESTIONNAIRE ASSESSING ACTIVITIES AND PARTICIPATION IN PATIENTS WITH SYSTEMIC SCLEROSIS: THE SCISCIF STUDY (2019) (0)
013 WHO surgical checklist in dermatology: compliance, attitudes, barriers (2016) (0)
A method of diagnosing systemic scleroderma or pulmonary hypertension (2009) (0)
Systemic Sclerosis : Results from 2 Large European Caucasian Cohorts Autoimmune Risk Loci in CD 58 and ITGAM , ITGAX , Association Study of YANNICK ALLANORE (2011) (0)
[Hand: a tool for the diagnosis and evaluation of consequences of diseases]. (2013) (0)
Physical and Occupational Therapy (2012) (0)
[Pregnancy in systemic sclerosis]. (2008) (0)
[Late-onset asthma in a traveler]. (2011) (0)
Patient acceptable symptom state and minimally clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of the sclereduc trial (2018) (0)
Validity, Reliability, and Differential Item Functioning of English and French Versions of the 10-Item Connor-Davidson Resilience Scale in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. (2023) (0)
Promotes Inflammation Impairs Macrophage Phagocytosis, and with Calreticulin on Apoptotic Neutrophils, Granulomatosis with Polyangiitis, Associates Proteinase 3, the Autoantigen in (2012) (0)
Mental Health Care Use and Associated Factors in Systemic Sclerosis: A Scleroderma Patient‐Centered Intervention Network Cohort Study (2022) (0)
[Reliability and validity of a workbook for assessment of professional competencies of internal medicine residents]. (2019) (0)
Title: Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide Short title: Exhaled CANO and scleroderma lung disease (2007) (0)
Digital Ischemia Induced by Fesoterodine. (2018) (0)
autoimmune encephalomyelitis immunoglobulin: a critical factor in controlling experimental Expansion of CD4+CD25+ regulatory T cells by intravenous (2013) (0)
[Pulmonary manifestations associated with immunosuppressive treatments used in transplantation and autoimmune diseases]. (2010) (0)
Differentiating tracheobronchial involvement in granulomatosis with polyangiitis and relapsing polychondritis on chest CT: a cohort study (2022) (0)
Differences in Disability Perception in Systemic Sclerosis: A Mirror Survey of Patients and Health Care Providers (2023) (0)
Systemic sclerosis (2017) (0)
OP0090 Determinants of Survival of Fetuses with Autoimmune Congenital Heart Block and Factors Associated with Neonatal and Late-Onset Dilated Cardiomyopathy: 214 Cases from the French Registry of Neonatal Lupus (2015) (0)
Computerized interstitial fibrosis quantification is the most powerful histological predictor of renal outcome in ANCA-associated vasculitis (2013) (0)
S.11.1 Influence of digital ulcer healing on disability and daily activity limitations in SSc (2012) (0)
Scleroderma renal crisis triggered by ibuprofen: Insights on complement-directed therapy (2023) (0)
Arthrose : quels enjeux en 2010 ? (2010) (0)
FRI0253 Use of bosentan for the prevention of digital ulcers related to systemic sclerosis. Retrospective french study of 89 patients treated since 2007 (2013) (0)
O29 Determination of homogenous subgroups of antiphospholipid syndrome: cluster analysis based on 509 cases (2020) (0)
Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. (2020) (0)
Frequency and impact on prognosis of signs of pulmonary veno-occlusive disease on high resolution computed tomography in patients with scleroderma associated pulmonary arterial hypertension (2011) (0)
SAT0649 DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED OUTCOME ASSESSING ACTIVITY LIMITATION AND PARTICIPATION RESTRICTION OF PATIENTS WITH SYSTEMIC SCLEROSIS: THE COCHIN 17-ITEM SCLERODERMA FUNCTIONAL SCALE (CSF-17) (2019) (0)
Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). (2018) (0)
SP0196 Delivering an Online Disease-Specific Rehabilitation Intervention: Examples from the SPIN Hand Project (2014) (0)
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET (2022) (0)
Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients. (2023) (0)
SAT0239 PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG–STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS (2019) (0)
Evaluation of Measurement Properties and Differential Item Functioning in English and French Versions of the UCLA Loneliness Scale-6: A Scleroderma Patient-Centered Intervention Network (SPIN) Study. (2023) (0)
THU0427 New Insights into the Presentation and the Management of Hepatitis B Reactivation in Patients with Immune Mediated Inflammatory Diseases (2013) (0)
Comprehensive icf core set and icf core set-derived activities and participation questionnaire for patients with systemic sclerosis: Results of the SCISCIF study (2018) (0)
OP0096 Relevance of the 6-Minute Walking Test in Assessing the Severity of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis, without Interstitial Lung Disease (2014) (0)
Proteinase 3 (PR3) is a phosphatidylserine-binding protein that can bind microparticles: Relevance in the context of granulomatosis with polyangiitis (GPA) (2013) (0)
Factors associated with major cardiovascular events in patients with primary systemic necrotizing vasculitides: Results of a longitudinal long-term follow-up study (2013) (0)
[Common variable immunodeficiency: one or multiple illnesses? 3 clinical cases]. (1999) (0)
SAT0226 MINOR SALIVARY GLAND BIOPSY TO DIAGNOSE LYMPHOMA IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME (2020) (0)
AB0620 High risk of mistaken classification of primary antiphospholipid syndrome as systemic lupus erythematosusaccording to the slicc criteria: analysis of a cohort of 214 antiphospholipid patients (2018) (0)
POS0317 THE PERFORMANCE OF DIFFUSING CAPACITY FOR MONOXIDE CARBON (DLCO) AND FORCED VITAL CAPACITY (FVC) IN PREDICTING THE ONSET OF SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD) IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE (2021) (0)
SAT0351 Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study OF34 Patients (2016) (0)
THU0275 SEVERE PREECLAMPSIA RELATED TO ANTIPHOSPHOLIPID SYNDROME: AN EUROPEAN STUDY OF 40 WOMEN (2020) (0)
Reply to the comment of Fayet et al. Obstacles and motivations to influenza and pneumococcal vaccination in patients with rheumatoid arthritis. A qualitative study. (2019) (0)
AB0467 REMISSION AND LOW DISEASE ACTIVITY STATE IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS: PREVALENCE AND IMPACT ON DAMAGE ACCRUAL (2020) (0)
Association cancer et syndrome des antisynthétases (2011) (0)
Cutaneous Involvement in Catastrophic Antiphospholipid Syndrome in a Multicenter Cohort of 65 Patients. (2022) (0)
Exploring research team members' and trial participants' perceptions of acceptability and implementation within one videoconference-based supportive care program for individuals affected by systemic sclerosis during COVID-19: a qualitative interview study. (2023) (0)
A qualitative interview study exploring the psychological health impacts of the SPIN-CHAT program among people with systemic sclerosis at the onset of COVID-19: perceptions of trial participants and research team members. (2023) (0)
Chapter-04 Neutrophils in ANCA-associated Vasculitis (2015) (0)
[Risk of infection and systemic inflammatory and/or autoimmune diseases: where do we stand in 2009?]. (2009) (0)
Detection of Antibodies to Tenascin-C in Patients with Idiopathic Pulmonary Arterial Hypertension. (2009) (0)
Lymphopénie CD4 idiopathique : suivi à long terme d’une cohorte de 36 patients (2012) (0)
Tumor Necrosis Factor-α Blockade and the Risk of Vasculitis (2004) (0)
New Insights into the Pathogenesis of Giant Cell Arteritis through a Genome-Wide Association Study (2016) (0)
Primary biliary cholangitis and systemic sclerosis (Reynolds syndrome): A case–control study (2021) (0)
Increased migration and proliferation potential characterized vascular smooth muscle cells from patients with giant cell arteritis (2013) (0)
[Treatment of scleroderma]. (2002) (0)
ORIGINAL ARTICLE Antibodies to fibroblasts in idiopathic and scleroderma associated pulmonary hypertension (2006) (0)
In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicenter study. (2023) (0)
AB0199 ASSESSING DISABILITY AND QUALITY OF LIFE IN ALGERIAN SYSTEMIC SCLEROSIS PATIENTS: CONSTRUCT VALIDITIES OF THE ARAB HAND FUNCTION INDEX AND HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) (2019) (0)
[Osteoarthritis: what are the challenges in 2010?]. (2010) (0)
Don't mix apples and oranges. Reply to Azoulay et al. (2022) (0)
12. New Registries (2018) (0)
Distal Lung Inflammation Assessed by Alveolar Concentration of Nitric Oxide Is an Individualised Biomarker of Severe COVID-19 Pneumonia (2022) (0)
After three years of health crisis, it is time to (finally) support general internal medicine! (2022) (0)
[Immunity, autoimmunity, aging]. (2008) (0)
Pulmonary Perspective Systemic Sclerosis-associated Pulmonary Arterial Hypertension (2010) (0)
Rapidly progressive glomerulonephritis is not the sole presentation of renal involvement in ANCA associated vasculitis (2013) (0)
SAT0323 Improvement of Digital Ulcerative Disease in Patients with Systemic Sclerosis is Associated with Better Functional Prognosis (2014) (0)
GENETIC DIAGNOSIS GUIDES TREATMENT OF AUTOIMMUNE ENTEROPATHY. (2022) (0)
[Autoantibodies in clinical practice]. (2006) (0)
Auteurs et Collaborateurs (2013) (0)
Evaluation of bladder-sphincter disorders sclerodermia: 69 patients (2011) (0)
Abstract 4383: Incidence of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis: A 3-Year Longitudinal Study (2008) (0)
Pulmonary arterial hypertension in idiopathic in fl ammatory myopathies Data from the French pulmonary hypertension registry and review of the literature (2016) (0)
method of diagnosing a pulmonary arterial hypertension. (2008) (0)
Osteitis in Systemic Sclerosis: A Nationwide Case–Control Retrospective Study (2020) (0)
Title The Scleroderma Patient-centered Intervention Network ( SPIN ) Cohort : Protocol for a cohort multiple randomised controlled trial ( cmRCT ) design to support trials of psychosocial and rehabilitation interventions in a rare disease context Permalink (2013) (0)
Anti-Vascular Smooth Muscle Cell Antibodies in the Serum of Patients with Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Bind to Cytoskeleton, Oxidative Stress and Cell Cycle Antigens. (2009) (0)
[What's new in internal medicine?]. (2015) (0)
[Chronic obstructive pulmonary disease: an autoimmune disease?]. (2012) (0)
[Interstitial lung disease in systemic sclerosis]. (2006) (0)
[Lymphocytic meningitis in a 70-year-old woman]. (2016) (0)
Clinical Impact of Digital Ulcers (2018) (0)
Sexual disorders in 83 patients with systemic sclerosis (2011) (0)
117. PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG– STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS (2019) (0)
Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis (2023) (0)
Prognostic value of automated assessment of interstitial lung disease on CT in systemic sclerosis. (2023) (0)
[Primary immune deficiencies: also found in adults. A diagnosis to be aware of]. (2006) (0)
PROTEINURIA AND HEMATURIA AFTER REMISSION INDUCTION ARE ASSOCIATED WITH OUTCOME IN ANCA-ASSOCIATED VASCULITIS. (2023) (0)
[Pulmonary involvement in systemic scleroderma]. (2011) (0)
Pneumopathies infiltrantes diffuses des connectivites (2005) (0)
Secondary vasculitis P 197 Thrombotic vasculopathy with neovascularisation associated with probably levamisole-contaminated cocaine : Report of 2 cases (2013) (0)
Tracheal and bronchial stenoses in granulomatosis with polyangiitis (Wegener) (GPA) (2013) (0)
[Intraparenchymal hemorrhage disclosing a primary angiitis of the central nervous system]. (2009) (0)
056. CHARACTERISTICS BY AUTOANTIBODY STATUS IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: THE EUROPEAN SCLERODERMA OBSERVATIONAL STUDY COHORT (2017) (0)
354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS (2019) (0)
Therapeutical indications of the intravenous immunoglobulin (except in autoimmune thrombopenic purpura) (2005) (0)
[Flu vaccine and auto-immune and/or inflammatory diseases]. (2011) (0)
Microangiopathie thrombotique compliquant un syndrome POEMS : cas clinique (2001) (0)
Survival and prognosis factors in systemic sclerosis: Data of a French multicenter cohort of incident patients, systematic review and meta-analysis of the literature (2017) (0)
FRI0343 Factors associated with major cardiovascular events in patients with primary systemic necrotizing vasculitides: results of a longitudinal long-term follow-up study (2013) (0)
FRI0287 EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS (2019) (0)
Rituximab plus methotrexate combination as a salvage therapy in persistently active granulomatosis with polyangiitis. (2021) (0)
AB0984 Development of a Juvenile Systemic Sclerosis Response Index (JSSRI) (2015) (0)
Épidémiologie, classification des connectivites (2018) (0)
[Immunomodulator effects of intravenous immunoglobulins in neurological autoimmune diseases]. (1995) (0)
PReS-FINAL-2284: SLE and complement deficiencies: a French multicentric retrospective study (2013) (0)
POS0323 ANTI PM-SCL ASSOCIATED AUTO IMMUNE DISEASES: MULTICENTRIC COHORT OF 128 PATIENTS (2021) (0)
Thrombopoietin-dependent Myelo-megakaryopoiesis Fuels Thromboinflammation and Worsens Antibody-mediated Chronic Renal Microvascular Injury. (2023) (0)
OP0030 GRANULOMATOSIS WITH POLYANGIITIS SUSTAINED REMISSION OFF-THERAPY: DATA FROM THE FRENCH VASCULITIS STUDY GROUP REGISTRY (2020) (0)
AB0787 Influence of digital ulcer healing on disability and daily activity limitations in systemic sclerosis (2013) (0)
Fabry disease - from diagnosis to treatment: analysis of 19 families in France and Switzerland (2005) (0)
[Inventory of training of internal medicine in France: Results of a national survey]. (2017) (0)
Acquired C1-Inhibitor Deficiency: 7 Patients Treated with Rituximab (2012) (0)
Autoimmune systemic diseases (2012) (0)
[Diagnosis of primary immune deficiencies in adults]. (2005) (0)
Identification of target antigens of anti-endothelial cell antibodies in patients with ANCA-associated systemic vasculitis: A proteomic approach (2013) (0)
immunoglobulin Inhibition of maturation and function of dendritic cells by intravenous (2013) (0)
Identification of an expression-based set of genes to predict the subset of patients with systemic scleroderma (SSc) (2016) (0)
Successful outcome under multiple therapy in two cases of anti-MDA5 dermatomyositis with severe cardiomyopathy and interstitial lung disease. (2023) (0)
Systemic sclerosis associated myopathy. (2022) (0)
Additional file 3: of Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis (2016) (0)
12 Pregnancy and Scleroderma (0)
[Management of patients with a suspicion of giant cell arteritis: Survey among general practitioners and specialists]. (2021) (0)
Potential defect in annexin-A1-dependent anti-inflammatory mechanisms in GPA: Its cleavage by PR3 and its inhibition by autoantibodies (2013) (0)
FRI0342 Identification of target antigens of anti-endothelial cell antibodies in patients with anca-associated systemic vasculitis: a proteomic approach (2013) (0)
Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease. (2022) (0)
Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients (2021) (0)
Anti-PM-Scl antibodies positive patients encompass three different groups with distinct prognosis. (2022) (0)
The Advantage of Specific Intravenous Immunoglobulin (sIVIG) on Regular IVIG: Experience of the Last Decade (2012) (0)
AB0453 Presentation and management of granulomatosis with polyangiitis (wegener’s) (gpa) central nervous system (cns) involvement (2013) (0)
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies (2022) (0)
Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group. (2020) (0)
Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study (2020) (0)
Additional file 4: of Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis (2016) (0)
[New insights into the pathogenesis of ANCA-positive vasculitides]. (2007) (0)
Identification of EPX variants in Human Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). (2023) (0)
[Contribution and limits of "OSCE", "long-case" and "global end-of-placement marking" as end-of-rotation assessment methods. Experience from two internal medicine wards]. (2022) (0)
Correction to: A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency (2020) (0)
Features of non-Hodgkin's lymphoma diagnosed in minor salivary gland biopsies from primary Sjögren's syndrome patients. (2021) (0)
[Atherosclerosis: an immunologic disease?]. (2006) (0)
Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography : a prospective study on 20 patients (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Luc Mouthon?

Luc Mouthon is affiliated with the following schools:

Luc Mouthon's Academic­Influence.com Rankings

Luc Mouthon's Degrees

Similar Degrees You Can Earn

Why Is Luc Mouthon Influential?

Luc Mouthon's Published Works

Published Works

What Schools Are Affiliated With Luc Mouthon?

Luc Mouthon's AcademicInfluence.com Rankings